Sanofi (SNYNF) Stock Forecast & Price Target

Compare

367 Followers

See the Price Targets and Ratings of:

All Analysts

Top Analysts

Premium

SNYNF Analyst Ratings

Moderate Buy

11 Buy

5 Hold

0 Sell

Based on 16 analysts giving stock ratings to

Sanofi

in the past 3 months

TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers in the past 3 months

SNYNF Stock 12 Month Forecast

Average Price Target

$129.31

▲(34.85%Upside)

Based on 16 Wall Street analysts offering 12 month price targets for Sanofi in the last 3 months. The average price target is $129.31 with a high forecast of $147.68 and a low forecast of $110.47. The average price target represents a 34.85% change from the last price of $95.89.

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"90":"$90","119":"$119","148":"$148","104.5":"$104.5","133.5":"$133.5"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":147.679537,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$147.68</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":129.31,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$129.31</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":110.468945,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$110.47</span>\n  </div></div>","useHTML":true}}],"tickPositions":[90,104.5,119,133.5,148],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Oct<br/>2024","6":"Jan<br/>2025","9":"Apr<br/>2025","12":"Jul<br/>2025","25":"Jul<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,96.54,100.47381053846155,104.40762107692308,108.34143161538462,112.27524215384616,116.2090526923077,120.14286323076924,124.07667376923078,128.0104843076923,131.94429484615387,135.8781053846154,139.81191592307692,143.74572646153848,{"y":147.679537,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,96.54,99.06076923076924,101.58153846153847,104.1023076923077,106.62307692307692,109.14384615384616,111.66461538461539,114.18538461538462,116.70615384615385,119.22692307692307,121.74769230769232,124.26846153846154,126.78923076923077,{"y":129.31,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,96.54,97.61145730769232,98.68291461538462,99.75437192307693,100.82582923076923,101.89728653846154,102.96874384615386,104.04020115384616,105.11165846153847,106.18311576923077,107.25457307692308,108.3260303846154,109.39748769230769,{"y":110.468945,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":94.5,"date":1719792000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 22,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 9, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 4</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":98.67,"date":1722470400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 17,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 10, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 4</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":106.35,"date":1725148800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 25,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 10, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 5</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":109.63,"date":1727740800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 23,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 10, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 6</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":104.11,"date":1730419200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 23,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 8, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 5</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":91.87,"date":1733011200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 15,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 8, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 5</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":91.06,"date":1735689600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 17,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 7, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":103.76,"date":1738368000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 21,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 8, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":100.51,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 21,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 10, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":104.6,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 24,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 11, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":106.86,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 30,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 15, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":96.61,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 33,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 14, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":96.54,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 25,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 11, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Highest Price Target$147.68

Average Price Target$129.31

Lowest Price Target$110.47

The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts

Emmanuel PapadakisDeutsche Bank

Deutsche Bank

$116.28

Hold

21.27%

Upside

Reiterated

07/17/25

Analysts Offer Insights on Healthcare Companies: Sanofi (Other OTC: SNYNF) and Sarepta Therapeutics (NASDAQ: SRPT)

Nicolas PauillacKepler Capital

Kepler Capital

$110.47

Hold

15.20%

Upside

Reiterated

07/10/25

Kepler Capital Remains a Hold on Sanofi (SNYNF)

David RisingerLeerink Partners

Leerink Partners

$133.73→$117.45

Buy

22.48%

Upside

Reiterated

07/09/25

Sanofi's Growth Potential: Buy Rating Maintained Amid Adjusted Price Target and Strong Dupixent Performance

Colin WhiteUBS

UBS

$133.73

Buy

39.46%

Upside

Reiterated

07/08/25

Analysts Are Bullish on These Healthcare Stocks: Sanofi (SNYNF), Regeneron (REGN)

Luisa HectorBerenberg Bank

Berenberg Bank

$137.21

Buy

43.10%

Upside

Reiterated

07/03/25

Analysts Offer Insights on Healthcare Companies: AbSci (NASDAQ: ABSI) and Sanofi (Other OTC: SNYNF)

James QuigleyGoldman Sachs

Goldman Sachs

$136.05→$119.77

Hold

24.91%

Upside

Reiterated

07/03/25

Sanofi (SNYNF) Receives a Hold from Goldman Sachs

Richard VosserJ.P. Morgan

J.P. Morgan

$127.91

Hold

33.39%

Upside

Reiterated

07/02/25

J.P. Morgan Sticks to Their Hold Rating for Sanofi (SNYNF)

Emily FieldBarclays

Barclays

$145.35→$133.73

Buy

39.46%

Upside

Reiterated

07/02/25

Barclays Sticks to Their Buy Rating for Sanofi (SNYNF)

Sachin JainBank of America Securities

Bank of America Securities

$143.03→$133.73

Buy

39.46%

Upside

Reiterated

07/01/25

Sanofi's Strong Sales and Promising Growth Justify Buy Rating Despite EPS SetbackWe forecast 1) EPS on sales with sales broadly in-line VA cons, but EPS c5% below cons, mostly higher R&D spend (expect to correct prior to print); 2) -2% vs cons with US Eur2.6bn comprising TRx +c9% QoQ, offset by usual small pricing/mix headwinds. Acceleration from COPD launch sees TRx growth at +c28% YoY, vs +29% and acceleration from +c24% for on continued strong launch; with US TRx still growing c16% YoY (continued windfall sales; 3) GM hardest to forecast, with 90bps YoY improvement, partly reflecting 1Q call commentary that 2/3 of GM improvement in 1Q was product mix/efficiencies (remainder was inventory revaluation in 1Q); 4) R&D 140bps worse YoY (related to SOBI in comparator Q); 5) OOI of -Eur944mn.

Benjamin Jackson CFAJefferies

Jefferies

$139.54

Buy

45.52%

Upside

Reiterated

06/05/25

Jefferies Reaffirms Their Buy Rating on Sanofi (SNYNF)

Seamus FernandezGuggenheim

Guggenheim

$125.59→$127.91

Buy

33.39%

Upside

Reiterated

06/02/25

Guggenheim Reaffirms Their Buy Rating on Sanofi (SNYNF)

Florent CespedesBernstein

Bernstein

$144.19

Buy

50.37%

Upside

Reiterated

06/02/25

Analysts Are Bullish on Top Healthcare Stocks: Nurix Therapeutics (NRIX), Sanofi (SNYNF)

Unknown AnalystMorgan Stanley

Not Ranked

Morgan Stanley

$116.28

Hold

21.27%

Upside

Initiated

06/02/25

Sanofi (SNYNF) Has a New Rating from Morgan Stanley

Rajesh KumarHSBC

HSBC

$151.17→$133.73

Buy

39.46%

Upside

Reiterated

04/28/25

Sanofi price target lowered to EUR 115 from EUR 130 at HSBCSanofi price target lowered to EUR 115 from EUR 130 at HSBC

Elmar KrausDZ BANK AG

DZ BANK AG

―

Buy

―

Reiterated

04/25/25

Analysts Offer Insights on Healthcare Companies: Sanofi (Other OTC: SNYNF), Roche Holding AG (Other OTC: RHHVF) and BioNTech SE (NASDAQ: BNTX)

Ranks

Any

Analyst Rating

Any

Upside/ Downside

Any

Action

Any

Emmanuel PapadakisDeutsche Bank

Deutsche Bank

$116.28

Hold

21.27%

Upside

Reiterated

07/17/25

Analysts Offer Insights on Healthcare Companies: Sanofi (Other OTC: SNYNF) and Sarepta Therapeutics (NASDAQ: SRPT)

Nicolas PauillacKepler Capital

Kepler Capital

$110.47

Hold

15.20%

Upside

Reiterated

07/10/25

Kepler Capital Remains a Hold on Sanofi (SNYNF)

David RisingerLeerink Partners

Leerink Partners

$133.73→$117.45

Buy

22.48%

Upside

Reiterated

07/09/25

Sanofi's Growth Potential: Buy Rating Maintained Amid Adjusted Price Target and Strong Dupixent Performance

Colin WhiteUBS

UBS

$133.73

Buy

39.46%

Upside

Reiterated

07/08/25

Analysts Are Bullish on These Healthcare Stocks: Sanofi (SNYNF), Regeneron (REGN)

Luisa HectorBerenberg Bank

Berenberg Bank

$137.21

Buy

43.10%

Upside

Reiterated

07/03/25

Analysts Offer Insights on Healthcare Companies: AbSci (NASDAQ: ABSI) and Sanofi (Other OTC: SNYNF)

James QuigleyGoldman Sachs

Goldman Sachs

$136.05→$119.77

Hold

24.91%

Upside

Reiterated

07/03/25

Sanofi (SNYNF) Receives a Hold from Goldman Sachs

Richard VosserJ.P. Morgan

J.P. Morgan

$127.91

Hold

33.39%

Upside

Reiterated

07/02/25

J.P. Morgan Sticks to Their Hold Rating for Sanofi (SNYNF)

Emily FieldBarclays

Barclays

$145.35→$133.73

Buy

39.46%

Upside

Reiterated

07/02/25

Barclays Sticks to Their Buy Rating for Sanofi (SNYNF)

Sachin JainBank of America Securities

Bank of America Securities

$143.03→$133.73

Buy

39.46%

Upside

Reiterated

07/01/25

Benjamin Jackson CFAJefferies

Jefferies

$139.54

Buy

45.52%

Upside

Reiterated

06/05/25

Jefferies Reaffirms Their Buy Rating on Sanofi (SNYNF)

Seamus FernandezGuggenheim

Guggenheim

$125.59→$127.91

Buy

33.39%

Upside

Reiterated

06/02/25

Guggenheim Reaffirms Their Buy Rating on Sanofi (SNYNF)

Florent CespedesBernstein

Bernstein

$144.19

Buy

50.37%

Upside

Reiterated

06/02/25

Analysts Are Bullish on Top Healthcare Stocks: Nurix Therapeutics (NRIX), Sanofi (SNYNF)

Unknown AnalystMorgan Stanley

Not Ranked

Morgan Stanley

$116.28

Hold

21.27%

Upside

Initiated

06/02/25

Sanofi (SNYNF) Has a New Rating from Morgan Stanley

Rajesh KumarHSBC

HSBC

$151.17→$133.73

Buy

39.46%

Upside

Reiterated

04/28/25

Sanofi price target lowered to EUR 115 from EUR 130 at HSBCSanofi price target lowered to EUR 115 from EUR 130 at HSBC

Elmar KrausDZ BANK AG

DZ BANK AG

―

Buy

―

Reiterated

04/25/25

Analysts Offer Insights on Healthcare Companies: Sanofi (Other OTC: SNYNF), Roche Holding AG (Other OTC: RHHVF) and BioNTech SE (NASDAQ: BNTX)

Stocks with the Highest Top Analyst Consensus in the Healthcare Sector

xxx

Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering Sanofi

1 Month

xxx

Success Rate

8/15 ratings generated profit

Average Return

-0.59%

reiterated a xxx

rating 15 days ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 1 Month would result in 53.33% of your transactions generating a profit, with an average return of -0.59% per trade.

3 Months

xxx

Success Rate

9/15 ratings generated profit

Average Return

+0.73%

reiterated a xxx

rating 16 days ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 3 Months would result in 60.00% of your transactions generating a profit, with an average return of +0.73% per trade.

1 Year

David RisingerLeerink Partners

Success Rate

18/31 ratings generated profit

Average Return

+3.64%

reiterated a buy rating 9 days ago

Copying David Risinger's trades and holding each position for 1 Year would result in 58.06% of your transactions generating a profit, with an average return of +3.64% per trade.

2 Years

xxx

Success Rate

13/21 ratings generated profit

Average Return

+8.18%

reiterated a xxx

rating 2 months ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 2 Years would result in 61.90% of your transactions generating a profit, with an average return of +8.18% per trade.

The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

SNYNF Analyst Recommendation Trends

Rating

Mar 25

Apr 25

May 25

Jun 25

Jul 25

Strong Buy

Buy

Hold

Sell

Strong Sell

total

In the current month, SNYNF has received 25 Buy Ratings, 11 Hold Ratings, and 0 Sell Ratings. SNYNF average Analyst price target in the past 3 months is 129.31.

Each month's total comprises the sum of three months' worth of ratings.

SNYNF Financial Forecast

SNYNF Earnings Forecast

Next quarter’s earnings estimate for SNYNF is $1.90 with a range of $1.61 to $2.13. The previous quarter’s EPS was $1.60. SNYNF beat its EPS estimate 0.00% of the time in the past 12 months, while its overall industry beat the EPS estimate 58.18% of the time in the same period. In the last calendar year SNYNF has Preformed in-line its overall industry.

SNYNF Sales Forecast

Next quarter’s sales forecast for SNYNF is $11.92B with a range of $11.41B to $12.32B. The previous quarter’s sales results were ―. SNYNF beat its sales estimates 0.00% of the time in past 12 months, while its overall industry beat sales estimates 47.45% of the time in the same period. In the last calendar year SNYNF has Preformed in-line its overall industry.

SNYNF Stock Forecast FAQ

What is SNYNF’s average 12-month price target, according to analysts?

Based on analyst ratings, Sanofi’s 12-month average price target is 129.31.

What is SNYNF’s upside potential, based on the analysts’ average price target?

Sanofi has 34.85% upside potential, based on the analysts’ average price target.

Can I see which stocks the top-ranking analysts are rating?

Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.

How can I follow the stock ratings of top Wall Street analysts?

Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.

Is SNYNF a Buy, Sell or Hold?

Sanofi has a consensus rating of Moderate Buy which is based on 11 buy ratings, 5 hold ratings and 0 sell ratings.

What is Sanofi’s price target?

The average price target for Sanofi is 129.31. This is based on 16 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
The highest analyst price target is $147.68 ,the lowest forecast is $110.47. The average price target represents 34.85% Increase from the current price of $95.89.

What do analysts say about Sanofi?

Sanofi’s analyst rating consensus is a Moderate Buy. This is based on the ratings of 16 Wall Streets Analysts.

How can I buy shares of SNYNF?

Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.

Become an Expert with TipRanks Premium

What am I Missing?

Make informed decisions based on Top Analysts' activity

Know what industry insiders are buying

Get actionable alerts from top Wall Street Analysts

Find out before anyone else which stock is going to shoot up

Get powerful stock screeners & detailed portfolio analysis

Subscribe Now See Plans & Pricing

Sanofi (SNYNF) Stock Forecast & Price Target

SNYNF Analyst Ratings

SNYNF Stock 12 Month Forecast

Average Price Target

Detailed List of Analyst Forecasts​

Best Analysts Covering Sanofi

SNYNF Analyst Recommendation Trends

SNYNF Financial Forecast

SNYNF Earnings Forecast

SNYNF Sales Forecast

SNYNF Stock Forecast FAQ

Become an Expert with TipRanks Premium

Detailed List of Analyst Forecasts